The benefit of the doubt: PD-L1 status in unresectable stage III NSCLC management

Transl Cancer Res. 2023 Mar 31;12(3):680-683. doi: 10.21037/tcr-22-2843. Epub 2023 Feb 23.

Authors

Marie-Helene Denault¹, Cheryl Ho²

Affiliations

¹ Department of Pneumologie, Centre de recherche de l'Institut universitaire de cardiologie et de pneumologie de Québec, Québec, QC, Canada.
² Department of Medical Oncology, BC Cancer, Vancouver, BC, Canada.

No abstract available

Keywords: Non-small cell lung cancer (NSCLC); immunotherapy; programmed death ligand-1 (PD-L1); unresectable stage III.

Publication types

Editorial
Comment